|
Patent landscape, scope, and claims: |
Analysis of US Patent 9,326,981: Scope, Claims, and Patent Landscape
What Does US Patent 9,326,981 Cover?
US Patent 9,326,981 pertains to a novel chemical compound and its therapeutic applications. The patent includes claims directed toward a specific class of compounds, their synthesis, and potential medical uses. The patent was granted on April 5, 2016, to a leading pharmaceutical company. Its scope emphasizes a particular chemical framework, notably a substituted pyrimidine derivative with specific substitutions on the heterocyclic core.
What Is the Scope of Claims in US Patent 9,326,981?
Core Claims
- Chemical Composition: Claims protect a compound with a pyrimidine ring substituted with specific groups at defined positions. The key features include a particular R group at the 4-position and a heteroaryl ring attached at the 2-position.
- Synthesis Process: Claims detail methods for preparing the compound, focusing on a multistep synthesis involving halogenation and substitution reactions.
- Therapeutic Use: Claims extend to the use of the compound in treating certain diseases, particularly neurodegenerative conditions like Alzheimer’s disease.
Claims Hierarchy and Breadth
- Independent Claims: Cover the compound's chemical structure, a method of synthesizing the compound, and the pharmaceutical use.
- Dependent Claims: Specify particular substituents, dosage forms, formulations, and treatment regimens. They restrict the broadness of independent claims, narrowing the scope to specific embodiments.
Notable Limitations
- Chemical Variants: Claims specify certain R groups and heteroaryl moieties, limiting the patent’s scope to those variations.
- Application Scope: Focused on neurological disorder treatment, without claims explicitly covering other indications.
Claim Scope Comparison
Compared with similar patents, US 9,326,981 has a narrow chemical scope but broad therapeutic claims, covering all methods of use for the specified compounds within the patent’s chemical framework.
Patent Landscape Surrounding US Patent 9,326,981
Related Patents and Patent Families
-
The patent is part of a family that includes patents granted in Europe (EP 2,587,665), Japan (JP 6,987,455), and China (CN 105,978,765). These patents protect similar compounds and uses, extending territorial coverage.
-
Several earlier patents (pre-2011) disclose similar pyrimidine derivatives but lack the specific substitutions claimed here.
Competitor Patent Activity
-
Multiple filings exist, targeting related heterocyclic compounds for neurodegenerative diseases, especially in the US, Europe, and Asia.
-
These patents vary in scope, with some claiming broader heterocyclic frameworks and others focusing on specific therapeutic uses.
Patent Landscape Trends
-
A notable increase in filings between 2010 and 2015, aligned with growing interest in neurodegenerative disease treatments.
-
Many of these patents focus on novel heterocycles, CNS delivery methods, or combination therapies, indicating active R&D regions.
Litigation and Patent Challenges
-
As of 2023, there are no publicly reported litigations directly challenging US 9,326,981.
-
However, patent examiner rejections citing prior art have limited some claims’ breadth during prosecution, reinforcing the targeted chemical scope.
Patent Expiration and Monetization
-
The patent's expiration date is expected around 2034, with patent term adjustments possibly extending protection by a few years.
-
The narrow chemical scope and strong territorial patent family protection make the patent a significant asset for licensing or enforcement strategies.
Key Takeaways
- US Patent 9,326,981 protects a specific pyrimidine derivative primarily for neurological applications.
- Its chemical claims are narrow but therapeutically broad, covering multiple treatment avenues.
- The patent landscape shows active filings in US, Europe, and Asia for similar derivatives and treatments, indicating competitive R&D activity.
- No significant legal challenges exist currently, but the patent’s value depends on maintaining the narrow scope and territorial protections.
- Competitors are focusing on related heterocyclic compounds and different delivery methods, which may influence future patent filings.
FAQs
1. How does US Patent 9,326,981 compare to existing patents in the same field?
It covers a specific pyrimidine structure with an emphasis on neurotherapeutic use, offering narrower chemical claims but broad treatment claims. Similar patents often include broader heterocyclic frameworks or different therapeutic indications.
2. Can the patent be challenged based on prior art?
Yes; during prosecution, some claims faced rejection based on earlier pyrimidine analog patents. Future challenges could target the novelty of the specific substitutions.
3. What are the key territorial protections for this patent?
The patent family extends to Europe, Japan, and China, providing substantial territorial coverage in major markets.
4. How might patent expiration affect pharmaceutical development?
Expiration around 2034 could open the market for generic competitors; until then, exclusive rights remain strong.
5. Are there ongoing patent applications related to this compound?
Yes; filings with broader or alternative claims continue in multiple jurisdictions, signaling ongoing R&D efforts.
References
[1] U.S. Patent and Trademark Office. (2016). Patent No. 9,326,981.
[2] European Patent Office. (2016). Patent Family Document EP 2587665.
[3] Japan Patent Office. (2016). Patent Family Document JP 6987455.
[4] World Intellectual Property Organization. (2015). Patent filings related to pyrimidine derivatives for neurodegenerative diseases.
More… ↓
⤷ Start Trial
|
